ArticleChinese medical journal2026
Correlation of G protein-coupled receptor and tumor microenvironment with gastric cancer outcomes and therapies.
Article in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Network toxicology and interpretable modeling identify nicotine-associated neuroendocrine targets and a three-gene prognostic signature in breast cancer.Translational cancer research · 2026Article
- Integrating multiple omics and machine learning to reveal the prognostic value of endoplasmic reticulum stress geneTranslational cancer research · 2026Article
- The mediating role of resourcefulness in the relationship between perceived stress and benefit finding among non-small cell lung cancer patients: a cross-sectional study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Comparative efficacy and safety of flexible and navigable suction sheath versus non-flexible suctioning ureteral access sheath in retrograde intrarenal surgery for renal stones: a propensity score-matched retrospective cohort study.World journal of urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) prognosis and treatment depend on tumor burden and gastric function, yet tumor progression and therapy resistance are influenced by intratumoral G protein-coupled receptors (GPCRs) and the tumor microenvironment (TME). This study aims to examine GPCR- and TME-related factors to enhance the understanding of GC prognostic and therapeutic predictions.
methodsThis study analyzed single-cell RNA sequencing data from the GEO dataset GSE167297 for stomach adenocarcinoma (STAD), bulk transcriptome data from the GEO cohort GSE62254 and TCGA-STAD cohort. Differentially expressed GPCR-related genes (GPCRRGs) were identified using limma, and immune cell proportions were estimated via Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT). Prognostic GPCRRGs were selected through univariable/multivariable Cox proportional hazards regression and least absolute shrinkage and selector operator (LASSO) regression to build a risk model, validated by Kaplan-Meier analysis. A GPCR-TME classifier integrated GPCR signatures and TME scores. Functional enrichment employed gene set enrichment analysis (GSEA) and weighted gene co-expression network analysis (WGCNA). scRNA-seq processing via Seurat included CellChat for cell interactions and tumor mutational burden (TMB) estimation. Tumor immune dysfunction and exclusion (TIDE) predicted immune checkpoint blockade (ICB) response. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed on 10 STAD tumor tissues collected from patients undergoing surgical resection at Shanxi Province Cancer Hospital.
resultsIn TCGA, 209 GPCRRGs were identified (145 upregulated, 64 downregulated). CIBERSORT revealed 20 immune cell types, with 11 prognostic. A model with 14 GPCRRGs and 11 TME immune cells stratified risk. The GPCR-TME classifier categorized patients into four subgroups: GPCRlow/TMEhigh (best prognosis), GPCRlow/TMElow, GPCRhigh/TMEhigh, and GPCRhigh/TMElow. GSEA showed extracellular matrix (ECM)-receptor and cytokine-receptor pathways enriched in high GPCR/TME groups. WGCNA linked modules to vasculature, cell cycle, and metabolism. scRNA-seq confirmed GPCR signatures, with CD8+ T and B cells as key expressors, and strong interactions between GPCRhigh immune clusters and tumor cells. GPCRlow/TMEhigh had the highest TMB and best prognosis; GPCRhigh/TMElow showed more TP53 mutations. Immune checkpoint patterns varied, aiding ICB response prediction. The classifier stratified ICB patients, with GPCRlow/TMEhigh demonstrating superior response rates. Proteomap analysis highlighted differential enrichment in immune signaling and metabolic pathways between responders and non-responders. qRT-PCR confirmed upregulation of c-x-c motif chemokine receptor 4, lysophosphatidic acid receptor 2, frizzled class receptor 2, and apelin receptor in STAD tissues.
conclusionThe GPCR-TME classifier offers pretreatment predictive value for prognosis and therapeutic responses, potentially enabling novel patient stratification for targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.